Minerva Neurosciences, Inc.

NERV · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.3%

Institutions93.3%

Public / Other

	You	Peer avg
P/E	–	11.6
Revenue Growth	–	+21.4%
ROE	–	-46.6%

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	–	–	$41.18M	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$15.10M	-$21.85M	-$25.23M	-$45.37M	$1.85M	-$75.87M	-$51.73M	-$41.17M	-$30.19M	-$26.11M
Operating income as a percentage of revenue.	–	–	–	–	4.5%	–	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$293.42M	$1.44M	-$32.11M	-$49.91M	$1.94M	-$72.18M	-$50.17M	-$31.52M	-$31.05M	-$27.08M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-34.67	$0.19	$-6.01	$-1.17	$0.05	$-1.00	$-1.00	$0.00	$0.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-34.67	$0.19	$-6.01	$-1.17	$0.05	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$82.30M	$21.36M	$36.09M	$60.76M	$25.36M	$21.41M	$50.23M	$26.05M	$82.98M	$14.28M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$97.97M	$37.14M	$55.09M	$77.12M	$57.63M	$77.50M	$139.14M	$183.70M	$132.94M	$82.58M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	–	$3.96M	$4.85M	$1.43M
Everything the company owes — debt, unpaid bills, and other obligations.	$233.76M	$62.84M	$75.11M	$69.15M	$4.96M	$49.72M	$48.87M	$52.10M	$26.96M	$27.26M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$140.75M	-$25.69M	-$20.02M	$7.98M	$52.66M	$27.78M	$90.26M	$131.60M	$105.98M	-$101.81M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$13.50M	-$19.60M	-$24.60M	-$24.60M	-$33.80M	-$43.43M	-$41.94M	$3.09M	-$25.69M	-$24.27M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	$16326	–	–	–	–	$52400	–	–
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	-$24.62M	–	–	–	–	$3.04M	–	–

Minerva Neurosciences, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Peer Comparison

Income Statement

Balance Sheet

Cash Flow Statement